MIRADOR360 Trademark

Trademark Overview


On Monday, March 4, 2024, a trademark application was filed for MIRADOR360 with the United States Patent and Trademark Office. The USPTO has given the MIRADOR360 trademark a serial number of 98432118. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, October 10, 2024. This trademark is owned by Mirador Therapeutics, Inc.. The MIRADOR360 trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing the service of collecting and analyzing patient data and genetic information for pharmaceutical drug development and diagnostics development (including companion diagnostics development and complementary diagnostics development); providing the service of collecting and analyzing patient data including genetic information for selecting and validating therapeutic targets for pharmaceutical development as well as for predicting, measuring or evaluating the performance of therapeutic molecules directed at therapeutic targets; providing the service of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for diagnostics (including companion diagnostics development and complementary diagnostics development) as well as for predicting, measuring or evaluating the performance of the diagnostics; providing the service of collecting and analyzing patient data including genetic information for selecting and valid...

General Information


Serial Number98432118
Word MarkMIRADOR360
Filing DateMonday, March 4, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, October 10, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkMIRADOR THREE SIXTY
Pseudo MarkMIRADOR THREE SIX ZERO
Pseudo MarkMIRADOR THREE HUNDRED SIXTY
Goods and ServicesProviding the service of collecting and analyzing patient data and genetic information for pharmaceutical drug development and diagnostics development (including companion diagnostics development and complementary diagnostics development); providing the service of collecting and analyzing patient data including genetic information for selecting and validating therapeutic targets for pharmaceutical development as well as for predicting, measuring or evaluating the performance of therapeutic molecules directed at therapeutic targets; providing the service of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for diagnostics (including companion diagnostics development and complementary diagnostics development) as well as for predicting, measuring or evaluating the performance of the diagnostics; providing the service of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for selecting patients for inclusion in clinical treatment (including clinical trials) as well as for predicting, measuring or evaluating the performance of the patient selecting criteria; providing the service of collecting patient data and genetic information and analysis of such data for identifying and recruiting patients for participation in clinical trials for pharmaceutical drug development, matching patients with clinical trials and for measuring and monitoring the performance of clinical trials for pharmaceutical drug development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating therapeutic targets and therapeutic molecules in the field of pharmaceutical development; providing a platform as a service featuring a computer software platform or computer service for selecting, validating and evaluating biomarkers and other patient-selecting or patient-identifying criteria in the field of diagnostic development (including companion diagnostics development and complementary diagnostics development)

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, March 4, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMirador Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Monday, March 4, 2024NEW APPLICATION ENTERED
Monday, July 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 10, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 10, 2024NON-FINAL ACTION WRITTEN
Thursday, October 10, 2024NON-FINAL ACTION E-MAILED
Wednesday, September 18, 2024ASSIGNED TO EXAMINER